1. State of the art methodologies for the estimation of fire costs in buildings to support cost–benefit analysisIkwulono David Unobe, Andrea Lucherini, Shuna Ni, Thomas Gernay, Ranjit Kumar Chaudhary, Ruben Van Coile, 2024, pregledni znanstveni članek Povzetek: Fires can lead to costly building damage as well as loss of lives and injuries. Installed to protect buildings from fire, or to limit the damage from such outbreaks, fire protection measures are a common feature in buildings. However, these features come at a cost. Although quite ubiquitous in buildings, the value of these features to private individuals and to society is not fully understood. To understand their value, a cost benefit analysis detailing the costs and benefits of fire protection measures is needed. Carrying out such an analysis requires methods for computing both the cost of these fire protection measures, and losses from fires (including both direct and indirect losses). This study outlines methodologies for evaluating those costs and losses. An exhaustive collection of available data necessary for estimating both costs and losses is presented. Several limitations in current methodologies and data constraints were identified, with recommendations proposed to address these shortcomings. Relevant sections of a study by the authors that refines fire protection cost estimation at national and sub-national levels are emphasized, including updated building categories, guidance on computing multipliers, and detailed cost calculation methods for installation and maintenance costs. The calculation uses regularly updated U.S. Census Bureau construction data, ensuring timely multiplier updates. The insights and suggestions presented in this study will ultimately refine the process of selecting fire protection strategies that maximize the net benefit of fire protection measures for both private stakeholders and society at large.
Ključne besede: fire protection measures, cost of fire protection, losses from fire, cost benefit analysis, installation costs, maintenance costs
Objavljeno v DiRROS: 18.04.2024; Ogledov: 57; Prenosov: 6
 Celotno besedilo (879,08 KB)
Gradivo ima več datotek! Več... |
2. The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia : discrepancy analysis between cost and reimbursementTanja Mesti, Biljana Mileva Boshkoska, Mitja Kos, Metka Tekavčič, Janja Ocvirk, 2015, izvirni znanstveni članek Povzetek: The aim of the study was to estimate the direct medical costs of metastatic colorectal cancer (mCRC) treated at the Institute of Oncology Ljubljana and to question the healthcare payment system in Slovenia. Methods. Using an internal patient database, the costs of mCRC patients were estimated in 2009 by examining (1) mCRC direct medical related costs, and (2) the cost difference between payment received by Slovenian health insurance and actual mCRC costs. Costs were analysed in the treatment phase of the disease by assessing the direct medical costs of hospital treatment with systemic therapy together with hospital treatment of side effects, without assessing radiotherapy or surgical treatment. Follow-up costs, indirect medical costs, and nonmedical costs were not included. Results. A total of 209 mCRC patients met all eligibility criteria. The direct medical costs of mCRC hospitalization with systemic therapy in Slovenia for 2009 were estimated as the cost of medications (cost of systemic therapy + cost of drugs for premedication) + labor cost (the cost of carrying out systemic treatment) + cost of lab tests + cost of imaging tests + KRAS testing cost + cost of hospital treatment due to side effects of mCRC treatment, and amounted to %3,914,697. The difference between the cost paid by health insurance and actual costs, estimated as direct medical costs of hospitalization of mCRC patients treated with systemic therapy at the Institute of Oncology Ljubljana in 2009, was %1,900,757.80. Conclusions. The costs paid to the Institute of Oncology Ljubljana by health insurance for treating mCRC with systemic therapy do not match the actual cost of treatment. In fact, the difference between the payment and the actual cost estimated as direct medical costs of hospitalization of mCRC patients treated with systemic therapy at the Institute of Oncology Ljubljana in 2009 was %1,900,757.80. The model Australian Refined Diagnosis Related Groups (AR-DRG) for cost assessment in oncology being currently used is probably one of the reasons for the discrepancy between pay-outs and actual costs. We propose new method for more precise cost assessment in oncology.
Ključne besede: cost of treatment, metastatic colorectal cancer, cost of targeted therapy, monitoring costs
Objavljeno v DiRROS: 17.04.2024; Ogledov: 55; Prenosov: 11
Celotno besedilo (730,95 KB) |
3. |
4. |
5. Availability and costs of medicines for the treatment of tuberculosis in EuropeGunar Günther, Lorenzo Guglielmetti, Claude Leu, Christoph Lange, Frank van Leth, 2022, pregledni znanstveni članek Povzetek: Objectives. To evaluate the access to comprehensive diagnostics and novel anti-tuberculosis medicines in European countries. Methods. We investigated access to genotypic and phenotypic M. tuberculosis drug susceptibility testing, availability of anti-tuberculosis drugs and calculated cost of drugs and treatment regimens at major tuberculosis treatment centers in countries of the World Health Organization (WHO) European region where rates of drug-resistant tuberculosis are highest among all WHO regions. Results are stratified by middle-income and high-income countries. Results. Overall, 43 treatment centers in 43 countries participated in the study. For WHO Group A drugs, the frequency of countries with availability of phenotypic drug susceptibility testing was as follows: 30/40 (75%) for levofloxacin, 33/40 (82%) for moxifloxacin, 19/40 (48%) for bedaquiline and 29/40 (72%) for linezolid, respectively. Overall, 36/43 (84%) and 24/43 (56%) of countries had access to bedaquiline and delamanid, while only 6/43 (14%) had access to rifapentine. Treatment of patients with extensively drug-resistant tuberculosis with a regimen including a carbapenem was only available in 17/43 (40%) of the countries. Median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicin-resistant tuberculosis (shorter regimen, including bedaquiline for six months) and extensively drug-resistant tuberculosis (including bedaquiline, delamanid and a carbapenem) were € 44 (min-max € 15-152), € 764 (min-max € 542-15152) and € 8709 (min-max € 7965-11759) in middle-income countries (n=12), and € 280 (min-max-€78-1084), € 29765 (min-max 11116-40584), € 217591 (min-max € 82827-320146) in high-income countries (n=29). Conclusion. In countries of the WHO Europe Region there is a widespread lack of drug susceptibility testing capacity to new and re-purposed anti-tuberculosis drugs, lack of access to essential medications in several countries and high treatment cost for drug-resistant tuberculosis.
Ključne besede: tuberculosis - drug therapy, Mycobacterium tuberculosis - drug therapy, health care costs - drug therapy, Europe
Objavljeno v DiRROS: 31.08.2022; Ogledov: 693; Prenosov: 144
 Povezava na datoteko |
6. Efficiency of group work in harvesting mountainous broadleaf thinning standsŽeljko Zečić, Ante P. B. Krpan, 2004, izvirni znanstveni članek Povzetek: Group work was researched for felling, processing, skidding and quality inspection activities in mountainous broadleaf thinning stands with approximately the same terrain and stand conditions. The stands were 55 and 70years old. In the forest communities of the mountainous beech forest with dead nettle (Lamio orvale - Fagetum sylvaticae/Ht. 1938) and the forests of the sessile oak and horn beam with beech (Epimedio - Carpinetum betuli var. Fagus sylvatica/Ht. 1938/Borth.1963), the main tree species are beech and sessile oak with the addition of other broadleaf species. Productivity was examined in two groups. The first comprised of five workers (A) and the secondof four workers (B). The first group was equipped with two tractors and three chain saws while the second used two tractors and two chain saws as wellas other necessary equipment. The effective time of the cutters spent on felling ranged from 36 to 42.9%, finishing and measurement took up 21%, while the effective time for the tractors ranged from 42.4 to 59%. The effective time per tree ranged from 3.62 to 3.77 minutes, i.e. from 8.46 min/m3 to 12.91min/m3 per unit. The daily output achieved by the Ecotrac and Torpedo tractors at a distance of 300 meters was 20.77.m3/day for group A, while the optimised output was 67.02 m3/day. The output achieved by both tractors in group B was 17.25 m3/day while the optimised output was 30.72 m3/day. The average performance per worker in group A was 4.15.m3/day while the optimised performance was 8.38 m3/day. For group B the average performance per worker was 4.31.m3/day and the optimised performance was 7.68 m3/day. The optimisation of the groups lowered the unit cost of production (300 m distance) for group A from 21.36 EUR/m3 to 6.62 EUR/m3, and for group B from 22.09 EUR/m3 to 12.41 EUR/m3.
Ključne besede: group work, thinnings, time study, productivity, costs
Objavljeno v DiRROS: 12.07.2017; Ogledov: 3928; Prenosov: 1727
Celotno besedilo (287,20 KB) |
